<ARTICLE> 5
<LEGEND>
This schedule contains summary financial information for the period ended
September 30, 1996, restated to reflect the combined results of Incyte
Pharmaceuticals, Inc. and Synteni, Inc.
</LEGEND>
<RESTATED>
<MULTIPLIER> 1,000
       
                             
<PERIOD-TYPE>                   9-MOS
<FISCAL-YEAR-END>                          DEC-31-1996
<PERIOD-START>                             JAN-01-1996
<PERIOD-END>                               SEP-30-1996
<CASH>                                          20,392
<SECURITIES>                                    29,946
<RECEIVABLES>                                    3,847
<ALLOWANCES>                                         0
<INVENTORY>                                          0
<CURRENT-ASSETS>                                55,381
<PP&E>                                          27,466
<DEPRECIATION>                                   7,314
<TOTAL-ASSETS>                                  76,003
<CURRENT-LIABILITIES>                           31,129
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                            22
<OTHER-SE>                                      32,232
<TOTAL-LIABILITY-AND-EQUITY>                    76,003
<SALES>                                              0
<TOTAL-REVENUES>                                27,604
<CGS>                                                0
<TOTAL-COSTS>                                        0
<OTHER-EXPENSES>                                32,352
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                   0
<INCOME-PRETAX>                                (7,260)
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                            (7,260)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                   (7,260)
<EPS-PRIMARY>                                   (0.33)
<EPS-DILUTED>                                   (0.33)